Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Sep 3;7(9):e2435901.
doi: 10.1001/jamanetworkopen.2024.35901.

Screening Familial Risk for Hereditary Breast and Ovarian Cancer

Daniel Kiser  1 , Gai Elhanan  1 , Alexandre Bolze  2 , Iva Neveux  1 , Karen A Schlauch  1 , William J Metcalf  1 , Elizabeth T Cirulli  2 , Catherine McCarthy  1 , Leslie A Greenberg  1 , Savanna Grime  3 , Jamie M Schnell Blitstein  3 , William Plauth  3 , Joseph J Grzymski  1   3
Affiliations

Screening Familial Risk for Hereditary Breast and Ovarian Cancer

Daniel Kiser et al. JAMA Netw Open. .

Abstract

Importance: Most patients with pathogenic or likely pathogenic (P/LP) variants for breast cancer have not undergone genetic testing.

Objective: To identify patients meeting family history criteria for genetic testing in the electronic health record (EHR).

Design, setting, and participants: This study included both cross-sectional (observation date, February 1, 2024) and retrospective cohort (observation period, January 1, 2018, to February 1, 2024) analyses. Participants included patients aged 18 to 79 years enrolled in Renown Health, a large health system in Northern Nevada. Genotype was known for 38 003 patients enrolled in Healthy Nevada Project (HNP), a population genomics study.

Exposure: An EHR indicating that a patient is positive for criteria according to the Seven-Question Family History Questionnaire (hereafter, FHS7 positive) assessing familial risk for hereditary breast and ovarian cancer (HBOC).

Main outcomes and measures: The primary outcomes were the presence of P/LP variants in the ATM, BRCA1, BRCA2, CHEK2, or PALB2 genes (cross-sectional analysis) or a diagnosis of cancer (cohort analysis). Age-adjusted cancer incidence rates per 100 000 patients per year were calculated using the 2020 US population as the standard. Hazard ratios (HRs) for cancer attributable to FHS7-positive status were estimated using cause-specific hazard models.

Results: Among 835 727 patients, 423 393 (50.7%) were female and 29 913 (3.6%) were FHS7 positive. Among those who were FHS7 positive, 24 535 (82.0%) had no evidence of prior genetic testing for HBOC in their EHR. Being FHS7 positive was associated with increased prevalence of P/LP variants in BRCA1/BRCA2 (odds ratio [OR], 3.34; 95% CI, 2.48-4.47), CHEK2 (OR, 1.62; 95% CI, 1.05-2.43), and PALB2 (OR, 2.84; 95% CI, 1.23-6.16) among HNP female individuals, and in BRCA1/BRCA2 (OR, 3.35; 95% CI, 1.93-5.56) among HNP male individuals. Being FHS7 positive was also associated with significantly increased risk of cancer among 131 622 non-HNP female individuals (HR, 1.44; 95% CI, 1.22-1.70) but not among 114 982 non-HNP male individuals (HR, 1.11; 95% CI, 0.87-1.42). Among 1527 HNP survey respondents, 352 of 383 EHR-FHS7 positive patients (91.9%) were survey-FHS7 positive, but only 352 of 883 survey-FHS7 positive patients (39.9%) were EHR-FHS7 positive. Of the 29 913 FHS7-positive patients, 19 764 (66.1%) were identified only after parsing free-text family history comments. Socioeconomic differences were also observed between EHR-FHS7-negative and EHR-FHS7-positive patients, suggesting disparities in recording family history.

Conclusions and relevance: In this cross-sectional study, EHR-derived FHS7 identified thousands of patients with familial risk for breast cancer, indicating a substantial gap in genetic testing. However, limitations in EHR family history data suggested that other identification methods, such as direct-to-patient questionnaires, are required to fully address this gap.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Drs Bolze and Grzymski reported holding patents (US Patent Application 63/467,250 and 18/652,745) outside the submitted work. Dr Grzymski also reported receiving grants from Gilead Sciences outside the submitted work. No other disclosures were reported.

References

    1. Grzymski JJ, Elhanan G, Morales Rosado JA, et al. . Population genetic screening efficiently identifies carriers of autosomal dominant diseases. Nat Med. 2020;26(8):1235-1239. doi:10.1038/s41591-020-0982-5 - DOI - PubMed
    1. Manickam K, Buchanan AH, Schwartz MLB, et al. . Exome sequencing-based screening for BRCA1/2 expected pathogenic variants among adult biobank participants. JAMA Netw Open. 2018;1(5):e182140. doi:10.1001/jamanetworkopen.2018.2140 - DOI - PMC - PubMed
    1. Abul-Husn NS, Soper ER, Odgis JA, et al. ; CBIPM Genomics Team; Regeneron Genetics Center . Exome sequencing reveals a high prevalence of BRCA1 and BRCA2 founder variants in a diverse population-based biobank. Genome Med. 2019;12(1):2. doi:10.1186/s13073-019-0691-1 - DOI - PMC - PubMed
    1. Elhanan G, Kiser D, Neveux I, et al. . Incomplete penetrance of population-based genetic screening results in electronic health record. Front Genet. 2022;13:866169. doi:10.3389/fgene.2022.866169 - DOI - PMC - PubMed
    1. Manchanda R, Blyuss O, Gaba F, et al. . Current detection rates and time-to-detection of all identifiable BRCA carriers in the Greater London population. J Med Genet. 2018;55(8):538-545. doi:10.1136/jmedgenet-2017-105195 - DOI - PubMed

Publication types

MeSH terms

Substances